

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
393/03662

In Re Application Of **Ehud DAFNI**

APR 19 2004

Serial No.  
10/676,461

Filing Date  
September 30, 2003

Examiner  
Unknown

Group Art Unit  
3736

Title: **ASSESSMENT OF VASCULAR DILATATION**

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
393/03662

In Re Application: **Clud DAFNI**

Serial No.

10/676-461

Filing Date

September 30, 2003

Examiner

Unknown

Group Art Unit

3736

**ASSESSMENT OF VASCULAR DILATATION**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **03-3419** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\_\_\_\_\_  
Signature of Person Mailing Correspondence

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

**\*This certificate may only be used if paying by deposit account.**

Dated: **March 29, 2004**

\_\_\_\_\_  
Signature

**Maier Fenster, Reg. No. 41,016**

**William H. Dippert, Esq.**  
**Reed Smith LLP**  
**599 Lexington Avenue, 29th Floor**  
**New York, NY 10022-7650**

**Tel: (212) 521-5400**

CC:

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


In regard to the application of: Ehud DAFNI

Serial No : 10/676,461

Group Art Unit: 3736

Filed : September 30, 2003

Examiner: Unknown

For  ASSESSMENT OF VASCULAR DILATATION

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant respectfully directs the attention of the Examiner to art cited with respect to the present application.

The Examiner is respectfully requested to review and consider this art, in accordance with MPEP 2001.06 and to indicate in the first office action that he has considered this art. Additionally, the Examiner is respectfully requested to cite those prior art publications mentioned in this application which the Examiner considers to be material or relevant to the present claims.

Further, in order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached is an Equivalent to Form PTO-1449 listing the cited art. Also attached are copies<sup>1</sup> of the art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

In accordance with MPEP Section 609 it is requested that each document cited [including any mentioned in Applicants' specification which is not repeated on the attached (or prior) PTO-1449 form(s) or equivalents thereof] be given thorough consideration and be cited of record in the prosecution history of the present application by initialing on the PTO-1449 form or its equivalent, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a

---

<sup>1</sup> To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the national stage file. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited then none is known to the undersigned.


393/03662

rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,  
Ehud DAFNI




Maier FENSTER  
Registration No. 41,016

March 29, 2004

William H. Dippert, Esq.  
Reed Smith LLP  
599 Lexington Avenue  
New York, NY 10022-7650

Tel: (212) 521-5400

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	ATTY DOCKET NO. 393/03662	SERIAL NO. 10/676,461
	APPLICANT(S) Ehud DAFNI	
	FILING September 30, 2003	GROUP 3736



### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	Filing date if appropriate
	1.	6,152,881	28 Nov '00	RAINES, J. K. et al.			


### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

### OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	2.	SCHACHINGER, V. et al.; "Prognostic Impact of Coronary Vasolidator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease"; Circulation, available on < <a href="http://www.circulationaha.org">http://www.circulationaha.org</a> >; April 25, 2000; pp. 1899-1906.
	3.	KADIRVELU, A. et al.; "Endothelial Dysfunction in Cardiovascular Diseases"; Medical Progress, May 2002; pp. 4-12.
	4.	SONDERGAARD, E. et al.; "Relationship Between Vascular Dysfunction in Peripheral Arteries and Ischemic Episodes During Daily Life in Patients With Ischemic Heart Disease and Hypercholesterolemia"; Am Heart Julius 144(1), Retrieved from the internet on < <a href="http://www.medscape.com/viewarticle/439533">http://www.medscape.com/viewarticle/439533</a> print>; 2002; 8 Pages.
	5.	CORRETTI, M. C. et al.; "Guidelines For the Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasolidation of the Brachial Artery"; Journal of the American College of Cardiology; Vol. 39; No. 2; 2002; pp. 257-265.
	6.	GRIMNES, S. et al.; "Bioimpedance and Bioelectricity Basics"; Academic Press; pp. 187-193, 271-275.

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop:  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on April 6, 2004  
Date

Geraldine Gress

Reed Smith LLP  
599 Lexington Avenue  
29th Floor  
New York, New York 10022-7650  
Tel: 212-521-5400; Fax: 212-521-5450

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Applicant: Ehud Dafni  
Serial No: 10/676,461  
Filing Date: September 30, 2003  
For: ASSESSMENT OF VASCULAR DILATATION  
Enclosures: (1) Transmittal of Information Disclosure Statement (3 pages); (2) Information Disclosure Statement (2 pages) w/IDS Citation (1 page) and six cited references;  
(3) Acknowledgement Postcard.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.